PRLog (Press Release) - Feb. 9, 2014 - NEW YORK -- Immune Response BioPharma, Inc. Today, Announces its Flagship Vaccine NeuroVax Granted Orphan Designation for Pediatric MS by the FDA.
http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfm?Index_Number=385412
The FDA Office of Orphan Products Development (OOPD) mission is to advance the evaluation and development of products (drugs, biologics, devices, or medical foods) that demonstrate promise for the diagnosis and/or treatment of rare diseases or conditions.
Orphan Drug Designation carries multiple benefits, including the availability of grant money, certain tax credits and seven years of market exclusivity, as well as the possibility of an expedited regulatory process.
“IRBP thanks the FDA for recognizing NeuroVax a novel vaccine to treat all forms of MS including children with this debilitating disease. NeuroVax is a first in class & best in class MS treatment. This is a very safe a once a month dosing therapeutic vaccine that will make treating pediatric MS more tolerable in the future once we move into pediatric studies” IRBP CEO Mr. Buswell commented.
About NeuroVax:
NeuroVax is a Once a Month Dosing injection, Safe, Tolerable, Enhances FOXP3+ Tregs & Regulates Pathogenic T Cells in MS Patients, a First in Class Disease Modifying Multiple Sclerosis Vaccine.
NeuroVax™ has been shown to stimulate strong, disease-specific cell-mediated immunity in nearly all treated patients. NeuroVax™ appears to work in part by enhancing levels of Foxp3+ Tregs, which may help regulate expression of pathogenic T cells in MS patients. The three TCRpeptides combined in NeuroVax™ correspond to one or more TCRgene families which are over expressed in 90% of MS patients. Previous clinical trials conducted by the Company and other independent researchers including a 27 patient clinical trial of NeuroVax have associated diminished levels of Foxp3+ Treg responses with the pathogenesis and progression of MS.This same mechanism appears to be important in the pathogenesis of other autoimmune diseases such as RA and psoriasis. Monthly vaccinations over one year with NeuroVax™ markedly expanded the capacity of regulatory T cells (Tregs) to recognize TCRs expressed by potentially pathogenic T cells. New data were also presented that showed NeuroVax™ produced a significant increase inTCR-specific T cells in patients with MS,including increases in interleukin-10-secreting T cells (IL-10) and Foxp3+ Tregs.
Immune Response BioPharma, Inc. Maybe Found on the World Wide Web @ www.immuneresponse.net
Media Contact
Immune Response BioPharma, Inc.
917 275-7931
@immuneresponsebiopharma.com
Help employers find you! Check out all the jobs and post your resume.
